Advanced Materials · 2018 · 292 citations · 30 references
PharmacyImmunologyOncologyDrug DeliveryImmunotherapyTumor MicroenvironmentCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationTumor Microenvironment ModulationCheckpoint Inhibitor AntibodiesImmune Checkpoint Combination TherapyImmune Checkpoint Inhibitor TherapyImmune Checkpoint LigandsMelanoma ImmunotherapyProgrammed Cell Death Ligand 1 InhibitionReactive Oxygen Species GenerationSustained Release Biomaterials
Although cancer immunotherapy based on immune checkpoint inhibitors holds great promise toward many types of cancers, several challenges still remain, associated with low objective response of patient rate as well as systemic side effects. Here, a combination immunotherapy strategy is developed based on a thermogelling reactive oxygen species (ROS)-responsive polypeptide gel for sustained release of anti-programmed cell death-ligand 1 antibody and dextro-1-methyl tryptophan, inhibitor of indoleamine-2,3-dioxygenase with leveraging the ROS level in the tumor microenvironment. This bioresponsive gel depot can effectively reduce the local ROS level and facilitate release of immunotherapeutics, which leads to enhanced anti-melanoma efficacy in vivo.
30
H <sub>2</sub> O <sub>2</sub> , a Necessary Evil for Cell Signaling
Sue Goo Rhee · Science · 2006 · 2.2K citations
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz, Ulrike Litzenburger, Felix Sahm et al. · Nature · 2011 · 1.9K citations · Full text
Medicine, Cancer Biology, Oncology +13
Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody
Chao Wang, Yanqi Ye, Gabrielle Hochu et al. · Nano Letters · 2016 · 772 citations
Life Sciences, Immunology, Oncology +17